Angiotensin-(1-7) Cardiovascular Effects in Aging
Key claim: A human study will test whether angiotensin-(1-7) reduces cardiovascular sympathetic outflow and blood pressure and improves endothelial function in older healthy adults.
Abstract
Aging is an independent risk factor for developing hypertension and cardiovascular disease; however, the mechanisms underlying age-related cardiovascular disease remain poorly understood. One hallmark of aging is an increase in sympathetic nervous system activity, which can decrease the number and/or sensitivity of β2 adrenergic receptors to reduce dilation of blood vessels and increase blood pressure. Identifying new targets to restore vascular β2 adrenergic receptor signaling may help reduce cardiovascular risk in aging. This study will test the hypothesis that angiotensin-(1-7), a protective hormone of the renin-angiotensin system, can reduce cardiovascular sympathetic outflow and blood pressure and improve endothelial function in older healthy humans.
Why this matters
Age-related sympathetic hyperactivity, rising blood pressure, and endothelial dysfunction sit upstream of most late-life cardiovascular events, and the protective ACE2/Ang-(1-7)/Mas arm of the renin-angiotensin system is a mechanistically attractive counterweight to the classical Ang-II axis targeted by existing antihypertensives. Moving Ang-(1-7) from rodent work into a controlled human probe is the step where that mechanistic story either begins to acquire outcome-relevant human data or fails to translate.